Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences

一种合胞病毒、呼吸道的技术，应用在从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗领域，能够解决感染性RSV拯救复杂等问题

Inactive Publication Date: 2007-08-08
UNITED STATES OF AMERICA
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Rescue of infectious RSV is complicated by multiple factors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
  • Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
  • Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences

Examples

Experimental program
Comparison scheme
Effect test

Embodiment I

[0137] Isolation and Identification of Mutagenized Derivative Strains of Cold Passage RSV

[0138] This example describes the chemical mutagenesis of incompletely attenuated, host range-restricted cpRSV to produce derivative ts and sp mutants with higher attenuation, which are suitable for the preparation of RSV vaccines.

[0139] Preparation of parental stocks of cold passaged RSV (cpRSV). Make Flow Laboratories Lot 3131 virus (the cpRSV parental virus of incomplete attenuation in the human body) go down twice in 25 ℃, MRC-5 cell, 25 ℃, terminally dilute (terminally dilute) twice in MRC-5 cell, then in MRC-5 was passaged three times to generate a cpRSV suspension for mutagenesis.

[0140] Make the parent stock in MRC-5 cells at 32°C with a concentration of 4×10 -4 Growth in M ​​5-fluorouracil medium induces cpRSV mutation. Basic studies have proven this concentration to be optimal, based on a 100-fold reduction in viral titer compared to media without ...

Embodiment II

[0264] Attenuation of cpRSV mutant strains by cold adaptation

[0265] This example describes the introduction of growth-limiting mutations into incompletely attenuated, host-range-restricted cpRSV strains by further passage of the strains at progressively lower temperatures to produce more satisfactorily attenuated human vaccines. Derivatives.

[0266] These cold adaptation (ca) methods were used to introduce further attenuation in the incompletely attenuated cpRSV3131 virus in seronegative children.

[0267] In the first strategy, parental stocks of cold-passaged RSV A2 (cpRSV3131 ) (obtained from Flow Laboratories) were prepared by passaging in MRC-5 cells at 25°C as described in Example 1 . Briefly, cold-passaged virus was inoculated into MRC-5 or Vero cell culture monolayers at a multiplicity of infection ≥0.01, and infected cells were incubated for 3-14 days before the next passage. The virus was passaged more than 20 times at 20-22°C to obtain a...

Embodiment III

[0272] Introduction of additional attenuating mutations into tsRSV

[0273] This example describes the use of a ts mutant as a parental virus to generate a more fully attenuated virus strain. For this purpose, two RSV A2ts mutants, ts-4 and ts-1 NG1, were selected. Two different approaches were chosen to introduce additional mutations into RSVts mutants. The first method is: carry out chemical mutagenesis on incompletely attenuated RSVts mutant strains, and select the mutagenized progenies with more sensitive plaque formation temperature for further analysis. The second method is to passage RSV ts mutant strains at low temperature and select ts mutant strains with ca phenotype, that is, mutant strains with higher replication ability than wild-type parental virus at suboptimal temperature.

[0274] Parental stocks of the ts-1 NG1 virus were prepared from live respiratory syncytial virus (A-2) ts-1 NG-1 mutant strains from Flow Laboratories Lot M4, virus grow...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. Alternatively, recombinant RSV and vaccine compositions thereof incorporate attenuating and other mutations specifying desired structural and or phenotypic characteristics in an infectious RSV. Recombinant RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of a selected nucleotide sequence, gene, or gene segment in an infectious RSV clone. The immune system of an individual is stimulated to induce protection against natural RSV infection, or multivalently against infection by RSV and another pathogen, such as PIV, by administration of attenuated, biologically derived or recombinant RSV.

Description

[0001] This application is a divisional application of a Chinese patent application with an application date of July 15, 1997, an application number of CN97196139.5, and an invention title of "Method for Preparing Attenuated Respiratory Syncytial Virus Vaccine from Cloned Nucleotide Sequence" . [0002] related application [0003] This application claims the benefits of U.S. Provisional Application Nos. 60 / 047,634 (filed May 23, 1997), 60 / 046,141 (filed May 9, 1997), 60 / 021,773 (filed June 15, 1996) Priority, and continuation-in-part, of these applications, which are hereby incorporated by reference. Background of the invention [0004] Human respiratory syncytial virus (RSV) is more important than all other microbial pathogens as a cause of pneumonia and bronchiolitis in infants under one year of age. Virtually all children become infected by the age of two years, and reinfection frequently occurs in older children and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N7/01C12N7/04A61K39/155C12N15/45C12N15/09A61K39/00A61P31/12C07K14/135C12N1/15C12N1/19C12N1/21C12N5/10
CPCC12N2760/18561C12N7/00A61K39/00C07K14/005C12N2760/18522A61P31/12A61P31/14C12N7/04
Inventor B·R·墨菲P·L·柯林斯S·S·怀特黑德A·A·布克列耶夫K·尤哈斯M·N·藤
Owner UNITED STATES OF AMERICA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com